Literature DB >> 10709801

Why are pharmacokinetic data summarized by arithmetic means?

S A Julious1, C A Debarnot.   

Abstract

The main aim of many studies in clinical pharmacology is to describe the pharmacokinetic activity of a given compound. This pharmacokinetic activity for an individual is then evaluated through a series of summary parameters, such as area under the concentration-time curve (AUC), maximum concentration (Cmax) and the rate constant lambda, and it is evaluated across individuals by descriptive statistics of these parameters, such as the mean and range and a measure of spread such as the standard deviation. How the pharmacokinetic parameters are derived is described here. It is demonstrated that the assumption of an exponential half-life is often fundamental to the derivation of pharmacokinetic parameters. Given this fact, one would think it logical that data are analyzed with the appropriate statistics on the log-scale and not by summary statistics, such as arithmetic means, on the original scale. Why arithmetic means are used to describe the data is explored and the special nature of the log-transformation highlighted.

Mesh:

Year:  2000        PMID: 10709801     DOI: 10.1081/BIP-100101013

Source DB:  PubMed          Journal:  J Biopharm Stat        ISSN: 1054-3406            Impact factor:   1.051


  15 in total

1.  All half-lives are wrong, but some half-lives are useful.

Authors:  J G Wright; A V Boddy
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

2.  A new reversible and potent P2Y12 receptor antagonist (ACT-246475): tolerability, pharmacokinetics, and pharmacodynamics in a first-in-man trial.

Authors:  Daniela Baldoni; Shirin Bruderer; Andreas Krause; Marcello Gutierrez; Pierre Gueret; Béatrice Astruc; Jasper Dingemanse
Journal:  Clin Drug Investig       Date:  2014-11       Impact factor: 2.859

3.  Sample size determination in bioequivalence studies using statistical assurance.

Authors:  A Ring; B Lang; C Kazaroho; D Labes; R Schall; H Schütz
Journal:  Br J Clin Pharmacol       Date:  2019-08-13       Impact factor: 4.335

4.  Statistical reporting of clinical pharmacology research.

Authors:  Arne Ring; Robert Schall; Yoon K Loke; Simon Day
Journal:  Br J Clin Pharmacol       Date:  2017-03-21       Impact factor: 4.335

5.  A Novel Loading Method for Doxycycline Liposomes for Intracellular Drug Delivery: Characterization of In Vitro and In Vivo Release Kinetics and Efficacy in a J774A.1 Cell Line Model of Mycobacterium smegmatis Infection.

Authors:  Rebekah K Franklin; Sarah A Marcus; Adel M Talaat; Butch K KuKanich; Ruth Sullivan; Lisa A Krugner-Higby; Timothy D Heath
Journal:  Drug Metab Dispos       Date:  2015-06-01       Impact factor: 3.922

6.  The potential of the estimands framework for clinical pharmacology trials: Some discussion points.

Authors:  Arne Ring; Martin J Wolfsegger
Journal:  Br J Clin Pharmacol       Date:  2020-03-03       Impact factor: 4.335

7.  The influence of sex, ethnicity, and CYP2B6 genotype on bupropion metabolism as an index of hepatic CYP2B6 activity in humans.

Authors:  Katarina Ilic; Roy L Hawke; Ranjit K Thirumaran; Erin G Schuetz; J Heyward Hull; Angela D M Kashuba; Paul W Stewart; Celeste M Lindley; Mei-Ling Chen
Journal:  Drug Metab Dispos       Date:  2012-12-13       Impact factor: 3.922

8.  Pharmacokinetics of the novel oral prostacyclin receptor agonist selexipag in subjects with hepatic or renal impairment.

Authors:  Priska Kaufmann; Hans G Cruz; Andreas Krause; Ivan Ulč; Atef Halabi; Jasper Dingemanse
Journal:  Br J Clin Pharmacol       Date:  2016-05-10       Impact factor: 4.335

9.  Variability in Human In Vitro Enzyme Kinetics.

Authors:  Christopher R Gibson; Ying-Hong Wang; Ninad Varkhede; Bennett Ma
Journal:  Methods Mol Biol       Date:  2021

10.  Investigation of the effects of ketoconazole on the pharmacokinetics of macitentan, a novel dual endothelin receptor antagonist, in healthy subjects.

Authors:  Jacob Atsmon; Jasper Dingemanse; Dimitri Shaikevich; Inna Volokhov; Patricia N Sidharta
Journal:  Clin Pharmacokinet       Date:  2013-08       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.